Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4

BACKGROUND: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. However, the efficacy of FOLFOX4 for HCC patients is st...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Asian Pac J Cancer Prev
Prif Awduron: Qin, Shukui, Zhang, Xinji, Guo, Wei, Feng, Jian, Zhang, Tianyi, Men, Lichuang, He, Jia
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: West Asia Organization for Cancer Prevention 2017
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5555527/
https://ncbi.nlm.nih.gov/pubmed/28610406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/APJCP.2017.18.5.1225
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg